Aviragen Therapeutics (AVIR) Misses Q1 EPS by 14c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.75), $0.14 worse than the analyst estimate of ($0.61).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00